Prevention of Mitochondrial Oxidative Damage as a Therapeutic Strategy in Diabetes
- Address correspondence and reprint requests to Dr. Michael P. Murphy, MRC Dunn Human Nutrition Unit, Wellcome Trust/MRC Bldg., Hills Rd., Cambridge CB2 2XY, U.K. E-mail: mpm{at}mrc-dunn.cam.ac.uk
Abstract
Hyperglycemia causes many of the pathological consequences of both type 1 and type 2 diabetes. Much of this damage is suggested to be a consequence of elevated production of reactive oxygen species by the mitochondrial respiratory chain during hyperglycemia. Mitochondrial radical production associated with hyperglycemia will also disrupt glucose-stimulated insulin secretion by pancreatic β-cells, because pancreatic β-cells are particularly susceptible to oxidative damage. Therefore, mitochondrial radical production in response to hyperglycemia contributes to both the progression and pathological complications of diabetes. Consequently, strategies to decrease mitochondrial radical production and oxidative damage may have therapeutic potential. This could be achieved by the use of antioxidants or by decreasing the mitochondrial membrane potential. Here, we outline the background to these strategies and discuss how antioxidants targeted to mitochondria, or selective mitochondrial uncoupling, may be potential therapies for diabetes.
- ΔμH+, proton electrochemical potential gradient
- AGE, advanced glycation end product
- DCF, dichlorofluorescein
- DNP, 2,4-dinitrophenol
- GSIS, glucose-stimulated insulin secretion
- MitoVit E, mitochondria-targeted derivative of α-tocopherol
- MnSOD, manganese superoxide dismutase
- ROS, reactive oxygen species
- UCP, uncoupling protein
Footnotes
-
M.P.M. is a paid consultant for Antipodean Biotechnology.
This article is based on a presentation at a symposium. The symposium and the publication of this article were made possible by an unrestricted educational grant from Les Laboratoires Servier.
-
- Accepted May 30, 2003.
- Received March 20, 2003.
- DIABETES














